A systematic review and meta-analysis of synthetic cathinone use and psychosis.
Addiction
Bath salts
Mental illness
Polysubstance use
Psychosis
Psychostimulant
Substance induced psychosis
Synthetic cathinones
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
04
09
2023
accepted:
29
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
Synthetic cathinones (SC), commonly referred to as "bath salts", are stimulants resembling the natural alkaloid cathinone found in the khat plant. These substances have the potential to induce serious health risks such as hallucinations, delusions, paranoia and agitation which can lead to substance-induced psychotic disorders. Despite growing concerns, there is a limited understanding of the association between SC consumption and the devolvement of such psychopathologies. We conducted a systematic review to investigate the frequency of substance-induced psychotic disorder (SIPD) and associated conditions in humans following synthetic cathinone consumption. We qualitatively and quantitatively analyzed SC exposure cases. A total of 32 studies were included, with a diverse range of demographics, synthetic cathinone types, and consumption patterns. The proportion of individuals developing psychotic symptoms was reported at 0.380 (Random-effects model, 95% CI 0.289 - 0.475). Additionally, the significant heterogeneity in diagnostic approaches limited our ability to provide a precise estimate of prevalence. Synthetic cathinone consumption is associated with the risk of developing psychotic symptoms as indicated by the prevalence of hallucinations and/or delusions. Due to the lack of information on classifying factors, particularly duration of symptoms, we are unable to conclude synthetic cathinone-induced psychosis. Further research is warranted to elucidate the underlying mechanism linking synthetic cathinone consumption and psychosis. This review underscores the urgency of addressing the growing health risks posed by synthetic cathinone use. Additionally, it highlights the necessity of proper quantification of psychotic symptoms through scales and reporting of classification criteria to accurately diagnose SIPD.
Identifiants
pubmed: 38446172
doi: 10.1007/s00213-024-06569-x
pii: 10.1007/s00213-024-06569-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Alexander PD, Gicas KM, Willi TS, Kim CN, Boyeva V, Procyshyn RM, Smith GN, Thornton AE, Panenka WJ, Jones AA, Vila-Rodriguez F, Lang DJ, William MacEwan G, Honer WG, Barr AM (2017) A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology 234(9–10):1535–1547. https://doi.org/10.1007/s00213-017-4551-7
doi: 10.1007/s00213-017-4551-7
pubmed: 28190084
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
Bäckberg M, Lindeman E, Beck O, Helander A (2015) Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clin Toxicol (phila) 53(1):46–53. https://doi.org/10.3109/15563650.2014.981823
doi: 10.3109/15563650.2014.981823
pubmed: 25422862
Barr AM, Phillips AG (2002) Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of D-amphetamine. Pharmacol Biochem Behav 71(1–2):293–299 ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11812535 )
doi: 10.1016/S0091-3057(01)00664-5
pubmed: 11812535
Barrio P, Gaskell M, Goti J, Vilardell S, Fàbregas JM (2016) Persistent psychotic symptoms after long-term heavy use of mephedrone: A two-case series. Adicciones 28(3):154–157. https://doi.org/10.20882/adicciones.824
doi: 10.20882/adicciones.824
pubmed: 27399224
Baumann MH (2014) Awash in a sea of “bath salts”: implications for biomedical research and public health. Addiction 109(10):1577–1579. https://doi.org/10.1111/add.12601
doi: 10.1111/add.12601
pubmed: 24984975
pmcid: 4896154
Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37(5):1192–1203. https://doi.org/10.1038/npp.2011.304
doi: 10.1038/npp.2011.304
pubmed: 22169943
Baumann MH, Walters HM, Niello M, Sitte HH (2018) Neuropharmacology of synthetic cathinones. Handb Exp Pharmacol 252:113–142. https://doi.org/10.1007/164_2018_178
doi: 10.1007/164_2018_178
pubmed: 30406443
pmcid: 7257813
Beck O, Franzen L, Bäckberg M, Signell P, Helander A (2015) Intoxications involving MDPV in Sweden during 2010–2014: Results from the STRIDA project. Clin Toxicol (phila) 53(9):865–873. https://doi.org/10.3109/15563650.2015.1089576
doi: 10.3109/15563650.2015.1089576
pubmed: 26462932
Beck O, Bäckberg M, Signell P, Helander A (2018) Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives. MDPV Copycats Clin Toxicol (phila) 56(4):256–263. https://doi.org/10.1080/15563650.2017.1370097
doi: 10.1080/15563650.2017.1370097
pubmed: 28895757
Blanco G, Vidler D, Roper C, Wood DM, Dargan PI, Keating L, Macfarlane R, Emmett S, Johnson G, Eddleston M, Hill SL, Thomas SHL (2021) Acute toxicity from the synthetic cathinone N-ethylpentylone (ephylone) in the United Kingdom. Clin Toxicol (phila) 59(12):1270–1273. https://doi.org/10.1080/15563650.2021.1909730
doi: 10.1080/15563650.2021.1909730
pubmed: 33855924
Boyda HN, Procyshyn RM, Tse L, Wong D, Pang CC, Honer WG, Barr AM (2012) Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 62(3):1391–1400 ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21376062 )
doi: 10.1016/j.neuropharm.2011.02.019
pubmed: 21376062
Britch SC, Walsh SL (2022) Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology 239(7):2063–2081. https://doi.org/10.1007/s00213-022-06125-5
doi: 10.1007/s00213-022-06125-5
pubmed: 35385972
pmcid: 8986509
Brookman F, Bennett TH, Hills R (2017) The pleasures and pains of mephedrone use: Perceptions of users and practitioners. Drugs: Education, Prevention and Policy 24(1):103–110. https://doi.org/10.1080/09687637.2016.1192106
doi: 10.1080/09687637.2016.1192106
Canada Border Services Agency (2023) Government of Canada. Retrieved 2023 Jul 13 from: https://www.cbsa-asfc.gc.ca/security-securite/seizure-saisie-eng.html
Capriola M (2013) Synthetic cathinone abuse. Clin Pharmacol 5:109–115. https://doi.org/10.2147/cpaa.s42832
doi: 10.2147/cpaa.s42832
pubmed: 23869180
pmcid: 3706256
Chou HH, Hsieh CH, Chaou CH, Chen CK, Yen TH, Liao SC, Seak CJ, Chen HY (2021) Synthetic cathinone poisoning from ingestion of drug-laced “instant coffee packets” in Taiwan. Hum Exp Toxicol 40(9):1403–1412. https://doi.org/10.1177/0960327121996043
doi: 10.1177/0960327121996043
pubmed: 33715482
Clark SR, Schubert KO, Olagunju AT, Lyrtzis EA, Baune BT (2018) Cognitive and functional assessment of psychosis stratification study (CoFAPSS): rationale, design, and characteristics. Front Psychiatry 9:662. https://doi.org/10.3389/fpsyt.2018.00662
doi: 10.3389/fpsyt.2018.00662
pubmed: 30559688
pmcid: 6287598
Corazza O, Valeriani G, Bersani FS, Corkery J, Martinotti G, Bersani G, Schifano F (2014) “Spice,” “kryptonite,” “black mamba”: an overview of brand names and marketing strategies of novel psychoactive substances on the web. J Psychoactive Drugs 46(4):287–294. https://doi.org/10.1080/02791072.2014.944291
doi: 10.1080/02791072.2014.944291
pubmed: 25188698
Crocker CE, Carter AJE, Emsley JG, Magee K, Atkinson P, Tibbo PG (2021) When cannabis use goes wrong: mental health side effects of cannabis use that present to emergency services. Front Psychiatry 12:640222. https://doi.org/10.3389/fpsyt.2021.640222
doi: 10.3389/fpsyt.2021.640222
pubmed: 33658953
pmcid: 7917124
Dargan PI, Albert S, Wood DM (2010) Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 103(11):875–879. https://doi.org/10.1093/qjmed/hcq134
doi: 10.1093/qjmed/hcq134
pubmed: 20675396
Daveluy A, Labadie M, Titier K, Courtois A, Penouil F, Castaing N, Haramburu F, Faure I, Cazanave C, Delile J, Latour V, Valdenaire G (2017) Poisoning by synthetic cathinones: Consumption behaviour and clinical description from 11 cases recorded by the Addictovigilance Centre of Bordeaux. Toxicologie Analytique Et Clinique 29(1):34–40. https://doi.org/10.1016/j.toxac.2016.11.005
doi: 10.1016/j.toxac.2016.11.005
De Felice LJ, Glennon RA, Negus SS (2014) Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. Life Sci 97(1):20–26. https://doi.org/10.1016/j.lfs.2013.10.029
doi: 10.1016/j.lfs.2013.10.029
pubmed: 24231923
Deeks JJ, Higgins JPT, Altman DG (editors) (2023) Chapter 10: analysing data and undertaking meta-analyses. In: JPT Higgins, J Thomas, J Chandler, M Cumpston, T Li, MJ Page, VA Welch (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook
Diestelmann M, Zangl A, Herrle I, Koch E, Graw M, Paul LD (2018) MDPV in forensic routine cases: Psychotic and aggressive behavior in relation to plasma concentrations. Forensic Sci Int 283:72–84. https://doi.org/10.1016/j.forsciint.2017.12.003
doi: 10.1016/j.forsciint.2017.12.003
pubmed: 29275216
Elliott L, Haddock CK, Campos S, Benoit E (2019) Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities. PLoS One 14(12):e0225273. https://doi.org/10.1371/journal.pone.0225273
doi: 10.1371/journal.pone.0225273
pubmed: 31794586
pmcid: 6890248
Fiorentini A, Cantù F, Crisanti C, Cereda G, Oldani L, Brambilla P (2021) Substance-induced psychoses: an updated literature review. Front Psychiatry 12:694863. https://doi.org/10.3389/fpsyt.2021.694863
doi: 10.3389/fpsyt.2021.694863
pubmed: 35002789
pmcid: 8732862
Fišar Z (2023) Biological hypotheses, risk factors, and biomarkers of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 120:110626. https://doi.org/10.1016/j.pnpbp.2022.110626
doi: 10.1016/j.pnpbp.2022.110626
pubmed: 36055561
Forrester MB (2012) Synthetic cathinone exposures reported to Texas poison centers. Am J Drug Alcohol Abuse 38(6):609–615. https://doi.org/10.3109/00952990.2012.677890
doi: 10.3109/00952990.2012.677890
pubmed: 22541001
Forrester MB (2013) Adolescent synthetic cathinone exposures reported to Texas poison centers. Pediatr Emerg Care 29(2):151–155. https://doi.org/10.1097/PEC.0b013e3182808ae2
doi: 10.1097/PEC.0b013e3182808ae2
pubmed: 23364377
Ganesh S, D’Souza DC (2022) Cannabis and psychosis: recent epidemiological findings continuing the “Causality Debate.” Am J Psychiatry 179(1):8–10. https://doi.org/10.1176/appi.ajp.2021.21111126
doi: 10.1176/appi.ajp.2021.21111126
pubmed: 34974754
Hazani HM, Naina Mohamed I, Muzaimi M, Mohamed W, Yahaya MF, Teoh SL, Pakri Mohamed RM, Mohamad Isa MF, Abdulrahman SM, Ramadah R, Kamaluddin MR, Kumar J (2022) Goofballing of opioid and methamphetamine: the science behind the deadly cocktail. Front Pharmacol 13:859563. https://doi.org/10.3389/fphar.2022.859563
doi: 10.3389/fphar.2022.859563
pubmed: 35462918
pmcid: 9021401
Honer WG, Cervantes-Larios A, Jones AA, Vila-Rodriguez F, Montaner JS, Tran H, Nham J, Panenka WJ, Lang DJ, Thornton AE, Vertinsky T, Barr AM, Procyshyn RM, Smith GN, Buchanan T, Krajden M, Krausz M, MacEwan GW, Gicas KM, Leonova O, Langheimer V, Rauscher A, Schultz K (2017) The hotel study-clinical and health service effectiveness in a cohort of homeless or marginally housed persons. Can J Psychiatry 62(7):482–492. https://doi.org/10.1177/0706743717693781
doi: 10.1177/0706743717693781
pubmed: 28199798
pmcid: 5528984
Huestis MA, Tyndale RF (2017) Designer drugs 2.0. Clin Pharmacol Ther 101(2):152–157. https://doi.org/10.1002/cpt.575
doi: 10.1002/cpt.575
pubmed: 28084644
Hyshka E, Strathdee S, Wood E, Kerr T (2012) Needle exchange and the HIV epidemic in Vancouver: lessons learned from 15 years of research. Int J Drug Policy 23(4):261–270. https://doi.org/10.1016/j.drugpo.2012.03.006
doi: 10.1016/j.drugpo.2012.03.006
pubmed: 22579215
pmcid: 3392518
IntHout J, Ioannidis JP, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25. https://doi.org/10.1186/1471-2288-14-25
doi: 10.1186/1471-2288-14-25
pubmed: 24548571
pmcid: 4015721
Jones AA, Vila-Rodriguez F, Leonova O, Langheimer V, Lang DJ, Barr AM, Procyshyn RM, Smith GN, Schultz K, Buchanan T, Krausz M, Montaner JS, MacEwan GW, Rauscher A, Panenka WJ, Thornton AE, Honer WG (2015) Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. BMJ Open 5(8):e008876. https://doi.org/10.1136/bmjopen-2015-008876
doi: 10.1136/bmjopen-2015-008876
pubmed: 26297373
pmcid: 4550735
Jones L, Reed P, Parrott A (2016) Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users. J Psychopharmacol 30(12):1313–1320. https://doi.org/10.1177/0269881116653106
doi: 10.1177/0269881116653106
pubmed: 27371497
Jones AA, Jang K, Panenka WJ, Barr AM, MacEwan GW, Thornton AE, Honer WG (2018) Rapid change in fentanyl prevalence in a community-based. High-Risk Sample JAMA Psychiatry 75(3):298–300. https://doi.org/10.1001/jamapsychiatry.2017.4432
doi: 10.1001/jamapsychiatry.2017.4432
pubmed: 29387869
Jones AA, Gicas KM, Seyedin S, Willi TS, Leonova O, Vila-Rodriguez F, Procyshyn RM, Smith GN, Schmitt TA, Vertinsky AT, Buchanan T, Rauscher A, Lang DJ, MacEwan GW, Lima VD, Montaner JSG, Panenka WJ, Barr AM, Thornton AE, Honer WG (2020) Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver. Canada Plos Med 17(7):e1003172. https://doi.org/10.1371/journal.pmed.1003172
doi: 10.1371/journal.pmed.1003172
pubmed: 32628679
Kamijo Y, Takai M, Fujita Y, Hirose Y, Iwasaki Y, Ishihara S, Yokoyama T, Yagi K, Sakamoto T (2014) A multicenter retrospective survey of poisoning after consumption of products containing synthetic chemicals in Japan. Intern Med 53(21):2439–2445. https://doi.org/10.2169/internalmedicine.53.2344
doi: 10.2169/internalmedicine.53.2344
pubmed: 25366001
Kapitány-Fövény M, Kertész M, Winstock A, Deluca P, Corazza O, Farkas J, Zacher G, Urbán R, Demetrovics Z (2013) Substitutional potential of mephedrone: an analysis of the subjective effects. Hum Psychopharmacol 28(4):308–316. https://doi.org/10.1002/hup.2297
doi: 10.1002/hup.2297
pubmed: 23881878
Kapitány-Fövény M, Kiss A, Farkas J, Kuczora KE, Pataki P, Horváth J, Demetrovics Z (2020) Childhood trauma, cognitive emotion regulation and motivation for behavior change among clients of opioid substitution treatment with and without past year synthetic cathinone use during therapy. Front Neurosci 14:37. https://doi.org/10.3389/fnins.2020.00037
doi: 10.3389/fnins.2020.00037
pubmed: 32082111
pmcid: 7004963
Kapitány-Fövény M, Farkas J, Pataki PA, Kiss A, Horváth J, Urbán R, Demetrovics Z (2017) Novel psychoactive substance use among treatment-seeking opiate users: The role of life events and psychiatric symptoms. Hum Psychopharmacol 32(3). https://doi.org/10.1002/hup.2602
Karila L, Megarbane B, Cottencin O, Lejoyeux M (2015) Synthetic cathinones: a new public health problem. Curr Neuropharmacol 13(1):12–20. https://doi.org/10.2174/1570159x13666141210224137
doi: 10.2174/1570159x13666141210224137
pubmed: 26074740
pmcid: 4462036
Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI (2018) The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res 194:78–85. https://doi.org/10.1016/j.schres.2017.04.016
doi: 10.1016/j.schres.2017.04.016
pubmed: 28416205
Kuropka P, Zawadzki M, Szpot P (2023) A review of synthetic cathinones emerging in recent years (2019–2022). Forensic Toxicol 41(1):25–46. https://doi.org/10.1007/s11419-022-00639-5
doi: 10.1007/s11419-022-00639-5
pubmed: 36124107
Leyrer-Jackson JM, Nagy EK, Olive MF (2019) Cognitive deficits and neurotoxicity induced by synthetic cathinones: is there a role for neuroinflammation? Psychopharmacology 236(3):1079–1095. https://doi.org/10.1007/s00213-018-5067-5
doi: 10.1007/s00213-018-5067-5
pubmed: 30368582
Liakoni E, Müller S, Stoller A, Ricklin M, Liechti ME, Exadaktylos AK (2017) Presentations to an urban emergency department in Bern, Switzerland associated with acute recreational drug toxicity. Scand J Trauma Resusc Emerg Med 25(1):26. https://doi.org/10.1186/s13049-017-0369-x
doi: 10.1186/s13049-017-0369-x
pubmed: 28264690
pmcid: 5340017
Lian L, Kim DD, Procyshyn RM, Fredrikson DH, Cázares D, Honer WG, Barr AM (2021) Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis. Early Interv Psychiatry. https://doi.org/10.1111/eip.13202
doi: 10.1111/eip.13202
pubmed: 34263540
Lin CH, Chen JJ, Chan CH (2023) Comparison of psychiatric and clinical profiles between people who use synthetic cathinones and methamphetamine: a matched case-control study. J Clin Psychopharmacol 43(2):122–130. https://doi.org/10.1097/jcp.0000000000001649
doi: 10.1097/jcp.0000000000001649
pubmed: 36706307
pmcid: 9988231
Lo LA, MacCallum CA, Yau JC, Barr AM (2022) Differences in those who prefer smoking cannabis to other consumption forms for mental health: what can be learned to promote safer methods of consumption? J Addict Dis 1–5. https://doi.org/10.1080/10550887.2022.2107332
Maher BA (2006) The relationship between delusions and hallucinations. Curr Psychiatry Rep 8(3):179–183. https://doi.org/10.1007/s11920-006-0021-3
doi: 10.1007/s11920-006-0021-3
pubmed: 19817067
Martin G, Copeland J (2010) Brief intervention for regular ecstasy (MDMA) users: Pilot randomized trial of a Check-up model. J Subst Use 15(2):131–142. https://doi.org/10.3109/14659890903075074
doi: 10.3109/14659890903075074
Martinotti G, De Risio L, Vannini C, Schifano F, Pettorruso M, Di Giannantonio M (2021) Substance-related exogenous psychosis: a postmodern syndrome. CNS Spectr 26(1):84–91. https://doi.org/10.1017/s1092852920001479
doi: 10.1017/s1092852920001479
pubmed: 32580808
McKetin R (2018) Methamphetamine psychosis: insights from the past. Addiction 113(8):1522–1527. https://doi.org/10.1111/add.14170
doi: 10.1111/add.14170
pubmed: 29516555
Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA (2016) Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci 10:153. https://doi.org/10.3389/fnins.2016.00153
doi: 10.3389/fnins.2016.00153
pubmed: 27147945
pmcid: 4835722
Murphy CM, Dulaney AR, Beuhler MC, Kacinko S (2013) “Bath salts” and “plant food” products: the experience of one regional US poison center. J Med Toxicol 9(1):42–48. https://doi.org/10.1007/s13181-012-0243-1
doi: 10.1007/s13181-012-0243-1
pubmed: 22733603
Murray RM, Englund A, Abi-Dargham A, Lewis DA, Di Forti M, Davies C, Sherif M, McGuire P, D’Souza DC (2017) Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology 124:89–104. https://doi.org/10.1016/j.neuropharm.2017.06.018
doi: 10.1016/j.neuropharm.2017.06.018
pubmed: 28634109
Murray B, Carpenter J, Dunkley C, Moran TP, Kiernan EA, Rianprakaisang T, Alsukaiti WS, Calello DP, Kazzi Z (2020) Single-agent bupropion exposures: clinical characteristics and an atypical cause of serotonin toxicity. J Med Toxicol 16(1):12–16. https://doi.org/10.1007/s13181-019-00749-4
doi: 10.1007/s13181-019-00749-4
pubmed: 31823333
Murrie B, Lappin J, Large M, Sara G (2020) Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull 46(3):505–516. https://doi.org/10.1093/schbul/sbz102
doi: 10.1093/schbul/sbz102
pubmed: 31618428
Ordak M, Nasierowski T, Muszynska E, Bujalska-Zadrozny M (2020) The psychiatric characteristics of people on a mephedrone (“bath salts”) Binge. Subst Use Misuse 55(10):1610–1617. https://doi.org/10.1080/10826084.2020.1753775
doi: 10.1080/10826084.2020.1753775
pubmed: 32306799
Orsolini L, Chiappini S, Papanti D, De Berardis D, Corkery JM, Schifano F (2019) The bridge between classical and “synthetic”/chemical psychoses: towards a clinical, psychopathological, and therapeutic perspective. Front Psychiatry 10:851. https://doi.org/10.3389/fpsyt.2019.00851
doi: 10.3389/fpsyt.2019.00851
pubmed: 31849723
pmcid: 6896660
Ortiz-Medina MB, Perea M, Torales J, Ventriglio A, Vitrani G, Aguilar L, Roncero C (2018) Cannabis consumption and psychosis or schizophrenia development. Int J Soc Psychiatry 64(7):690–704. https://doi.org/10.1177/0020764018801690
doi: 10.1177/0020764018801690
pubmed: 30442059
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):89. https://doi.org/10.1186/s13643-021-01626-4
doi: 10.1186/s13643-021-01626-4
pubmed: 33781348
pmcid: 8008539
Paquette CE, Pollini RA (2018) Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: A systematic review. Drug Alcohol Depend 188:239–250. https://doi.org/10.1016/j.drugalcdep.2018.03.049
doi: 10.1016/j.drugalcdep.2018.03.049
pubmed: 29787966
pmcid: 5999584
Paul LD, Welter-Luedeke J, Penzel S, Zangl A, Graw M (2021) Alpha-Pyrrolidinopentiothiophenone (α-PVT): A forensic case study including plasma concentrations. Forensic Sci Int 321:110721. https://doi.org/10.1016/j.forsciint.2021.110721
doi: 10.1016/j.forsciint.2021.110721
pubmed: 33640778
Peters BD, Karlsgodt KH (2015) White matter development in the early stages of psychosis. Schizophr Res 161(1):61–69. https://doi.org/10.1016/j.schres.2014.05.021
doi: 10.1016/j.schres.2014.05.021
pubmed: 24893908
Procyshyn RM, Barr AM, Flynn S, Schenk C, Ganesan S, Honer WG (2010) Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study. Schizophr Res 123(2–3):273–275. https://doi.org/10.1016/j.schres.2010.07.016
doi: 10.1016/j.schres.2010.07.016
pubmed: 20688481
Ramos-Miguel A, Beasley CL, Dwork AJ, Mann JJ, Rosoklija G, Barr AM, Honer WG (2015) Increased SNARE protein-protein interactions in orbitofrontal and anterior cingulate cortices in Schizophrenia. Biol Psychiatry 78(6):361–373. https://doi.org/10.1016/j.biopsych.2014.12.012
doi: 10.1016/j.biopsych.2014.12.012
pubmed: 25662103
Ramos-Miguel A, Barakauskas V, Alamri J, Miyauchi M, Barr AM, Beasley CL, Rosoklija G, Mann JJ, Dwork AJ, Moradian A, Morin GB, Honer WG (2019) The SNAP25 interactome in ventromedial caudate in schizophrenia includes the mitochondrial protein ARF1. Neuroscience 420:97–111. https://doi.org/10.1016/j.neuroscience.2018.12.045
doi: 10.1016/j.neuroscience.2018.12.045
pubmed: 30610939
Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB (2021) PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews(). J Med Libr Assoc 109(2):174–200. https://doi.org/10.5195/jmla.2021.962
doi: 10.5195/jmla.2021.962
pubmed: 34285662
pmcid: 8270366
Ricci V, Ceci F, Di Carlo F, Lalli A, Ciavoni L, Mosca A, Sepede G, Salone A, Quattrone D, Fraticelli S, Maina G, Martinotti G (2021) Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug Alcohol Depend 229(Pt A):109118. https://doi.org/10.1016/j.drugalcdep.2021.109118
doi: 10.1016/j.drugalcdep.2021.109118
pubmed: 34688166
Roberti JW (2004) A review of behavioral and biological correlates of sensation seeking. J Res Pers 38(3):256–279. https://doi.org/10.1016/S0092-6566(03)00067-9
doi: 10.1016/S0092-6566(03)00067-9
Sadeg N, Darie A, Vilamot B, Passamar M, Frances B, Belhadj-Tahar H (2014) Case report of cathinone-like designer drug intoxication psychosis and addiction with serum identification. Addict Disord Treat 13(1):38–43. https://doi.org/10.1097/ADT.0b013e318285308d
doi: 10.1097/ADT.0b013e318285308d
Schifano F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, Corkery JM, Vento A (2020) The clinical challenges of synthetic cathinones. Br J Clin Pharmacol 86(3):410–419. https://doi.org/10.1111/bcp.14132
doi: 10.1111/bcp.14132
pubmed: 31674690
pmcid: 7080616
Schreck B, Guerlais M, Laforgue E, Bichon C, Grall-Bronnec M, Victorri-Vigneau C (2020) Cathinone use disorder in the context of slam practice: new pharmacological and clinical challenges. Front Psychiatry 11:705. https://doi.org/10.3389/fpsyt.2020.00705
doi: 10.3389/fpsyt.2020.00705
pubmed: 32792999
pmcid: 7387686
Sedler MJ (1995) Understanding delusions. Psychiatr Clin North Am 18(2):251–262
doi: 10.1016/S0193-953X(18)30053-4
pubmed: 7659597
Simão AY, Antunes M, Cabral E, Oliveira P, Rosendo LM, Brinca AT, Alves E, Marques H, Rosado T, Passarinha LA, Andraus M, Barroso M, Gallardo E (2022) An Update on the Implications of New Psychoactive Substances in Public Health. Int J Environ Res Public Health 19(8). https://doi.org/10.3390/ijerph19084869
Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (phila) 49(6):499–505. https://doi.org/10.3109/15563650.2011.590812
doi: 10.3109/15563650.2011.590812
pubmed: 21824061
Stiles BM, Fish AF, Cook CA, Silva V (2016) Bath salt-induced psychosis: nursing assessment, diagnosis, treatment, and outcomes. Perspect Psychiatr Care 52(1):68–78. https://doi.org/10.1111/ppc.12101
doi: 10.1111/ppc.12101
pubmed: 25624142
Substance Abuse and Mental Health Services Administration (SAMHSA) (2020) Treatment of Stimulant Use Disorders. Substance Abuse and Mental Health Services Administration
Tang Y, Martin NL, Cotes RO (2014) Cocaine-induced psychotic disorders: presentation, mechanism, and management. J Dual Diagn 10(2):98–105. https://doi.org/10.1080/15504263.2014.906133
doi: 10.1080/15504263.2014.906133
pubmed: 25392252
Tanti M, Cosgrove J, Kelleher C, Jones R, Maguire M (2021) Acute neurological consequences of novel psychoactive substance use: a retrospective review in a large UK hospital. Clin Med (lond) 21(3):189–194. https://doi.org/10.7861/clinmed.2020-0706
doi: 10.7861/clinmed.2020-0706
pubmed: 33947659
Telles-Correia D, Moreira AL, Gonçalves JS (2015) Hallucinations and related concepts-their conceptual background. Front Psychol 6:991. https://doi.org/10.3389/fpsyg.2015.00991
doi: 10.3389/fpsyg.2015.00991
pubmed: 26283978
pmcid: 4515540
Thornton SL, Gerona RR, Tomaszewski CA (2012) Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 8(3):310–313. https://doi.org/10.1007/s13181-012-0232-4
doi: 10.1007/s13181-012-0232-4
pubmed: 22528592
pmcid: 3550171
Tse L, Procyshyn RM, Fredrikson DH, Boyda HN, Honer WG, Barr AM (2014) Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol 29(3):125–137 ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=24169026 )
doi: 10.1097/YIC.0000000000000014
pubmed: 24169026
Umebachi R, Aoki H, Sugita M, Taira T, Wakai S, Saito T, Inokuchi S (2016) Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning. Clin Toxicol (phila) 54(7):563–567. https://doi.org/10.3109/15563650.2016.1166508
doi: 10.3109/15563650.2016.1166508
pubmed: 27227375
United Nations Office of Drugs and Crime. (2022). Large seizures of synthetic cathinones in Europe reflect their growing importance on the illicit stimulants market UNODC EWA. Retrieved 2023 Aug 8 from https://www.unodc.org/LSS/Announcement/Details/189e540f-515b-475a-b9d2-30b6868bb454
Valento M, Lebin J (2017) Emerging drugs of abuse: synthetic cannabinoids, phenylethylamines (2C Drugs), and synthetic cathinones. Clin Pediatr Emerg Med 18(3):203–211. https://doi.org/10.1016/j.cpem.2017.07.009
doi: 10.1016/j.cpem.2017.07.009
Vallersnes OM, Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, Dargan PI (2016) Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry 16:293. https://doi.org/10.1186/s12888-016-1002-7
doi: 10.1186/s12888-016-1002-7
pubmed: 27538886
pmcid: 4990880
Walther S, Lefebvre S, Conring F, Gangl N, Nadesalingam N, Alexaki D, Wüthrich F, Rüter M, Viher PV, Federspiel A, Wiest R, Stegmayer K (2022) Limbic links to paranoia: increased resting-state functional connectivity between amygdala, hippocampus and orbitofrontal cortex in schizophrenia patients with paranoia. Eur Arch Psychiatry Clin Neurosci 272(6):1021–1032. https://doi.org/10.1007/s00406-021-01337-w
doi: 10.1007/s00406-021-01337-w
pubmed: 34636951
Warrick BJ, Hill M, Hekman K, Christensen R, Goetz R, Casavant MJ, Wahl M, Mowry JB, Spiller H, Anderson D, Aleguas A, Gummin D, Thomas R, Nezlek C, Smolinske S (2013) A 9-state analysis of designer stimulant, “bath salt,” hospital visits reported to poison control centers. Ann Emerg Med 62(3):244–251. https://doi.org/10.1016/j.annemergmed.2012.12.017
doi: 10.1016/j.annemergmed.2012.12.017
pubmed: 23540815
Wearne TA, Cornish JL (2018) A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psychiatry 9:491. https://doi.org/10.3389/fpsyt.2018.00491
doi: 10.3389/fpsyt.2018.00491
pubmed: 30364176
pmcid: 6191498
Weinstein AM, Rosca P, Fattore L, London ED (2017) Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry 8:156. https://doi.org/10.3389/fpsyt.2017.00156
doi: 10.3389/fpsyt.2017.00156
pubmed: 28878698
pmcid: 5572353
Weng TI, Chen LY, Chen JY, Chen PS, Hwa HL, Fang CC (2020) Characteristics of analytically confirmed illicit substance-using patients in the Emergency Department. J Formos Med Assoc 119(12):1827–1834. https://doi.org/10.1016/j.jfma.2020.01.005
doi: 10.1016/j.jfma.2020.01.005
pubmed: 32037264
Weng TI, Chen HY, Chin LW, Chou HH, Wu MH, Chen GY, Chen JY, Shih CP, Lin CC, Fang CC (2022a) Comparison of clinical characteristics between meth/amphetamine and synthetic cathinone users presented to the emergency department. Clin Toxicol (phila) 60(8):926–932. https://doi.org/10.1080/15563650.2022.2062376
doi: 10.1080/15563650.2022.2062376
pubmed: 35438590
Weng TI, Chen LY, Chen HY, Yu JH, Su YJ, Liu SW, Tracy DK, Chen YC, Lin CC, Fang CC (2022b) Gender differences in clinical characteristics of emergency department patients involving illicit drugs use with analytical confirmation. J Formos Med Assoc 121(9):1832–1840. https://doi.org/10.1016/j.jfma.2022.03.007
doi: 10.1016/j.jfma.2022.03.007
pubmed: 35365378
White CM (2016) Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV): synthetic cathinones with serious health implications. J Clin Pharmacol 56(11):1319–1325. https://doi.org/10.1002/jcph.742
doi: 10.1002/jcph.742
pubmed: 27029951
Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G, Skerrett D, Phillips ML, David AS, Peduto A, Gordon E (2004) Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry 161(3):480–489. https://doi.org/10.1176/appi.ajp.161.3.480
doi: 10.1176/appi.ajp.161.3.480
pubmed: 14992974
Yeh HT, Chen HY, Liu SW, Weng TI, Fang CC, Yu JH, Chen YC, Su YJ, Gao SY, Lin CC (2022) Clinical presentations and predictors of in-hospital mortality in illicit drug users in the new psychoactive substances (NPS) endemic era in Taiwan. Toxics 10(7). https://doi.org/10.3390/toxics10070386
Yuen JWY, Kim DD, Procyshyn RM, Panenka WJ, Honer WG, Barr AM (2021) A focused review of the metabolic side-effects of clozapine. Front Endocrinol (lausanne) 12:609240. https://doi.org/10.3389/fendo.2021.609240
doi: 10.3389/fendo.2021.609240
pubmed: 33716966
Zhou S, Shen C (2022) Avoiding definitive conclusions in meta-analysis of heterogeneous studies with small sample sizes. JAMA Otolaryngol Head Neck Surg 148(11):1003–1004. https://doi.org/10.1001/jamaoto.2022.2847
doi: 10.1001/jamaoto.2022.2847
pubmed: 36136342
Zimmerman L, Kilwein TM, Beyer D, Marks C, Looby A (2019) “Not for Human Consumption”: A descriptive investigation into user characteristics, motives, and consequences associated with bath salt use. J Psychoactive Drugs 51(3):218–224. https://doi.org/10.1080/02791072.2019.1571652
doi: 10.1080/02791072.2019.1571652
pubmed: 30724703